LU005
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Trial overview
Disease | Lung cancer treatment and diagnosis |
Topic | LU005 |
Description | Primary Objective:To compare progression free survival (PFS) and overall survival (OS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab.Patient Population:Patients with pathologically (histologically or cytologically) proven diagnosis of limited stage (Tx, T1-T4, N0-3, M0) small cell lung cancer (LS-SCLC) who have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry. |
Physicians | Dr. Alvaro A. MartinezMD, FACR, FABS, FASTRO Radiation Oncologist Works at 5 centers.Dr. Frank A. ViciniMD, FACR, FASTRO Radiation oncologist Works at 3 centers.Dr. Larry L. KestinMD, FACR Radiation Oncologist Works at 3 centers.Dr. Thomas BoikeMD Radiation Oncologist Works at 3 centers.Dr. Michael I. GhilezanMD, PhD Radiation Oncologist Works at 4 centers.Dr. John Vito AntonucciMD Radiation Oncologist Works at 4 centers. |